[A25-157] Iptacopan (complement 3 glomerulopathy) – Benefit assessment according to §35a Social Code Book V
Last updated 16.03.2026
Project no.:
A25-157
Commission:
Commission awarded on 15.12.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Kidneys and urinary system
Indication:
Adults with complement 3 glomerulopathy
Result of dossier assessment:
- Iptacopan as add-on therapy to mycophenolate mofetil and corticosteroids: added benefit not proven (based on the results of the relevant study)
- Iptacopan monotherapy: added benefit not proven (no relevant study)
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-157
| Project no. | Title | Status |
|---|---|---|
| G25-16 | Iptacopan (complement 3 glomerulopathy) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |
| G24-16 | Iptacopan (paroxysmal nocturnal haemoglobinuria with haemolytic anaemia) – Assessment according to §35a SGB V (1), Sentence 11 | Commission completed |
| A25-156 | Iptacopan (paroxysmal nocturnal haemoglobinuria) – Benefit assessment according to §35a Social Code Book V | Commission completed |